Novo Nordisk Outlines Likely COVID-19 Crisis Trial Impacts

Group Heralds Semaglutide’s Positive Phase II NASH Outcome

 
• By Sten Stovall

Novo Nordisk said late stage clinical trials near completion would not be hit by the pandemic but that delays to other stage studies were likely, and new ones were now “on hold.”

Novo_Nordisk
GLP-1 semaglutide met its primary endpoint in the Phase II proof-of-concept study • Source: Shutterstock

Novo Nordisk AS used a strong quarterly update to dampen concerns over COVID-19’s impact on its late-stage pipeline, saying the global pandemic was not expected to delay trials that were already close to finalization. But it did warn that recruitment of new patients for ongoing trials would be hit, delaying them.

The Danish diabetes and obesity specialist group also said it had put plans for any new clinical trials on hold, so as not to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D